EMA Authorised: Fotivda (tivozanib) — Recordati Netherlands B.V.

View source ↗

Summary

Fotivda (tivozanib) has been authorised by the EMA for use in carcinomas of the renal cell type.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• FOTIVDA (tivozanib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell. MAH: Recordati Netherlands B.V.. Decision date: 17/07/2023